Damora Therapeutics (DMRA) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 93.1% versus a gain of 46.5%. Over five years, TYRA leads with a +22.2% price change compared with -76.0% for DMRA. Tyra Biosciences is the larger company by market cap ($1.37 billion vs $1.30 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | TYRA |
|---|---|---|
| Share price | $21.08 | $19.94 |
| Market cap | $1.30B | $1.37B |
| 1-day change | +2.53% | -0.15% |
| YTD return | -10.65% | -24.04% |
| 1-year return | +93.05% | +46.52% |
| 5-year return | -75.95% | +22.22% |
| EPS (TTM) | $-0.25 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $40.65 |
| 52-week low | $4.95 | $13.29 |
| Distance from 52-week high | -45.00% | -50.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +122.44% | +137.96% |
| Average volume | 531.94K | 859.95K |
| Shares outstanding | 61.74M | 68.76M |
| Employees | 7 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed TYRA by 46.5 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
DMRA vs TYRA FAQ
Which is bigger, Damora Therapeutics or Tyra Biosciences?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.37B compared with $1.30B for Damora Therapeutics (DMRA).
Which stock has performed better over the past year, DMRA or TYRA?
DMRA returned +93.05% over the past 12 months, compared with +46.52% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.